Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-02-26 AGM Information
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Kangstem Biotech. It outlines the date, location, and agenda items (financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting's purpose and to request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2025-02-26 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains details about the meeting agenda, director candidates, and financial statements for the purpose of proxy solicitation. This falls under the category of Proxy Solicitation & Information Statement.
2025-02-26 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (퓨어스템오에이 키트 주(FURESTEM-OA Kit Inj.)(OSCA)의 제1/2a 임상시험계획 변경승인)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure filed by Kangstem Biotech regarding the approval of a clinical trial plan amendment by the Ministry of Food and Drug Safety (MFDS). It details the clinical trial objectives, methodology, and the specific nature of the amendment (storage and shelf-life). As this is a mandatory regulatory disclosure of material business information (major management matters) filed with the exchange, it falls under the 'Regulatory Filings' category.
2025-01-31 Korean
[기재정정]증권신고서(합병)
M&A Activity Classification · 100% confidence The document is a '증권신고서(합병) 정정신고' (Amended Securities Registration Statement for Merger) filed by Kangstem Biotech. It details the amendments made to a previously submitted merger registration statement, including changes to the merger background, business impact, and risk factors. This is a formal regulatory filing required for corporate mergers and acquisitions in South Korea, which falls under the category of M&A Activity (TAR).
2025-01-31 Korean
[기재정정]주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Kangstem Biotech regarding a change in the record date for shareholder list closure due to a merger schedule adjustment. It is a formal regulatory announcement filed with the KRX (Korea Exchange) system. Since it does not fit into specific categories like financial reports, director dealings, or dividend announcements, and is a standard regulatory disclosure, it falls under the RNS (Regulatory Filings) category.
2025-01-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a significant change in revenue or profit/loss structure (30% or more). This is a standard mandatory disclosure for listed companies in Korea when financial results deviate significantly from the previous period. It provides key financial highlights and reasons for the variance, which fits the definition of an Earnings Release (ER) as it is an initial announcement of financial results before the full audit report is finalized. FY 2024
2025-01-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.